Last Updated: June 18, 2026

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DAPAGLIFLOZIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed Bristol-Myers Squibb Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed AstraZeneca Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00263276 ↗ A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed Bristol-Myers Squibb Phase 2 2005-12-01 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DAPAGLIFLOZIN

Condition Name

Condition Name for DAPAGLIFLOZIN
Intervention Trials
Type 2 Diabetes Mellitus 57
Diabetes Mellitus, Type 2 57
Type 2 Diabetes 56
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DAPAGLIFLOZIN
Intervention Trials
Diabetes Mellitus, Type 2 207
Diabetes Mellitus 204
Heart Failure 63
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DAPAGLIFLOZIN

Trials by Country

Trials by Country for DAPAGLIFLOZIN
Location Trials
Canada 226
Mexico 122
United Kingdom 109
China 104
India 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DAPAGLIFLOZIN
Location Trials
Texas 83
California 68
Florida 62
New York 51
North Carolina 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DAPAGLIFLOZIN

Clinical Trial Phase

Clinical Trial Phase for DAPAGLIFLOZIN
Clinical Trial Phase Trials
PHASE4 39
PHASE3 35
PHASE2 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DAPAGLIFLOZIN
Clinical Trial Phase Trials
Completed 184
Recruiting 167
Not yet recruiting 87
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DAPAGLIFLOZIN

Sponsor Name

Sponsor Name for DAPAGLIFLOZIN
Sponsor Trials
AstraZeneca 179
Bristol-Myers Squibb 49
The University of Texas Health Science Center at San Antonio 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DAPAGLIFLOZIN
Sponsor Trials
Other 622
Industry 313
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.